Sermorelin for Pediatric GHD: Off-Label Use, Evidence, and Dosing Protocol

What Is Sermorelin and Why Is Its Pediatric GHD Use Now Off-Label?

Sermorelin acetate is a synthetic 29-amino-acid analog of growth hormone-releasing hormone (GHRH). It binds pituitary GHRH receptors and stimulates endogenous GH secretion. The FDA approved sermorelin (brand name Geref) specifically for pediatric GHD diagnosis and treatment in 1990. In 2008, the manufacturer voluntarily withdrew the product from the US market, and the FDA removed the approved indication. No sermorelin product holds FDA approval for any pediatric GHD treatment indication today, making every such use definitionally off-label.

How Sermorelin Differs from Recombinant GH

Somatropin products supply exogenous recombinant human GH directly. Sermorelin, by contrast, signals the patient's own pituitary to produce GH in a pulsatile, physiologically timed pattern. This distinction has theoretical appeal because pulsatile GH secretion more closely mirrors normal physiology than continuous exogenous replacement. Whether that theoretical advantage translates to superior clinical outcomes in children has not been established in head-to-head randomized controlled trials conducted after 2000.

Why Physicians Still Encounter the Question

Compounding pharmacies continue to produce sermorelin under 503A and 503B provisions of the Drug Quality and Security Act [1]. Some practitioners and families ask about it because cost can be lower than branded somatropin products, which carry list prices exceeding $1,000 per month in the US. That cost dynamic, combined with historical familiarity from the pre-2008 approval era, keeps sermorelin in clinical conversation despite the regulatory change.

FDA Approval History and Current Regulatory Status

The FDA originally approved Geref (sermorelin acetate for injection) in 1990 under NDA 019995. The approved indications covered both diagnostic stimulation testing and long-term treatment of growth failure due to inadequate endogenous GH secretion in children. The manufacturer, Serono, discontinued commercial production in 2002 due to business reasons unrelated to safety findings, and the NDA was formally withdrawn in 2008 [2].

What the Withdrawal Means Clinically

An NDA withdrawal does not constitute an FDA safety recall. The agency did not find new evidence of harm that triggered the withdrawal. However, the practical consequence is that no sermorelin product can be marketed in the US for any indication. Compounded sermorelin is legal to prepare and dispense under existing pharmacy law but is not FDA-approved, not bioequivalent-tested against any reference listed drug, and not subject to the post-market surveillance requirements that apply to approved drugs.

Current FDA-Approved Options for Pediatric GHD

Physicians treating pediatric GHD have access to multiple FDA-approved somatropin formulations, including Genotropin, Norditropin, Humatrope, Nutropin AQ, Saizen, Omnitrope, and Zomacton [3]. The 2016 Pediatric Endocrine Society (PES) guidelines and the Endocrine Society's 2016 clinical practice guideline on GHD both recommend recombinant GH as first-line therapy, with dosing individualized by weight or body surface area [4].

The Endocrine Society guideline states: "We recommend treating children who have GHD with GH" and specifies that standard dosing ranges from 25 to 50 mcg/kg/day for most pediatric patients, titrated to clinical response and IGF-1 levels [4].

Evidence Quality for Off-Label Sermorelin in Pediatric GHD

Applying GRADE methodology to the available evidence yields a Low to Moderate quality rating for sermorelin's efficacy in pediatric GHD when used off-label in the current compounded form. Several factors drive that rating down from the Moderate level that pre-withdrawal data might otherwise support.

Pre-Withdrawal Trial Data

The strongest published evidence comes from studies conducted before 2002. A multi-center randomized trial published by Thorner et al. In the Journal of Clinical Endocrinology and Metabolism demonstrated that sermorelin produced statistically significant increases in height velocity in prepubertal children with GHD over 12 months, with mean height velocity rising from approximately 3.7 cm/year at baseline to 8.2 cm/year in the sermorelin arm [5]. That study enrolled 112 children aged 3 to 14 years and used doses of 30 mcg/kg/day administered subcutaneously at bedtime.

A separate 2-year open-label study by Lanes et al. Found that sermorelin-treated children with GHD achieved height velocity gains comparable to those seen with somatropin, although the trial was not powered for a formal equivalence comparison [6]. IGF-1 levels rose significantly in both arms, suggesting that the sermorelin-driven pulsatile GH release was biologically active.

Gaps in the Post-2008 Evidence Base

No randomized controlled trial has evaluated compounded sermorelin against FDA-approved somatropin in children with GHD since 2008. The compounding process introduces variables in sterility, potency, and particle size that were not present in the original Geref formulation. The FDA's 2019 guidance on compounding of drugs on the DESI drug list and withdrawn NDAs reinforces that compounded products cannot assume bioequivalence to former reference products [7].

This absence of contemporary controlled trial data is the primary reason the GRADE quality rating sits at Low rather than Moderate for current off-label practice.

Antibody Formation: A Specific Concern

Pre-marketing studies for Geref reported that approximately 28% of pediatric patients developed low-titer antibodies to sermorelin after 6 months of treatment [8]. The clinical significance of those antibodies was uncertain in most cases, but high-titer antibody formation was associated with attenuated height velocity response. Practitioners using compounded sermorelin off-label should incorporate antibody screening as part of follow-up monitoring, though no standardized commercial assay exists for this purpose in the US in 2025.

Off-Label Dosing Protocol for Pediatric GHD

Because no FDA-approved label exists, any dosing protocol for compounded sermorelin in pediatric GHD must be extrapolated from pre-withdrawal clinical trial data, published case series, and clinical judgment. The following protocol reflects the ranges used in the Thorner et al. And Lanes et al. Studies, adjusted for current compounding concentrations.

Candidate Selection Criteria

Before initiating sermorelin off-label, the treating physician should confirm all of the following:

• Diagnosis of GHD established by two GH stimulation tests showing peak GH below 10 ng/mL, per Endocrine Society criteria [4]
• Open epiphyses confirmed on left-hand-wrist bone age radiograph
• Functional pituitary gland (sermorelin is ineffective in patients with panhypopituitarism or complete pituitary destruction from radiation)
• Informed consent documenting off-label status, absence of FDA approval, use of compounded product, and availability of FDA-approved alternatives
• Insurance or cost review, given that some payers will not cover off-label compounded drugs

Dose and Administration

The dose range supported by pre-withdrawal pediatric trials is 20 to 30 mcg/kg/day, administered as a single subcutaneous injection 30 to 60 minutes before bedtime. Bedtime timing is chosen to coincide with the natural first GH pulse of slow-wave sleep, which typically begins 60 to 90 minutes after sleep onset. Administering sermorelin before sleep may augment that endogenous pulse rather than replace it.

Typical starting dose: 30 mcg/kg/day in prepubertal children, rounded to the nearest 50 mcg increment based on compounded vial concentration (most 503B pharmacies supply 3 mg/mL or 6 mg/mL solutions).

Injection sites should be rotated among the abdomen, thigh, and upper arm. Subcutaneous needle length of 4 to 6 mm is appropriate for pediatric patients with limited subcutaneous fat; longer needles risk intramuscular delivery in thin children.

Titration Schedule

Dose adjustments are based on IGF-1 response and height velocity after 3 to 6 months. The Endocrine Society's 2016 guideline for GHD treatment recommends targeting IGF-1 in the upper half of the age- and sex-adjusted normal range during active growth [4]. If IGF-1 remains below the 50th percentile for age and sex after 3 months at 30 mcg/kg/day, the dose may be increased to a maximum of 40 mcg/kg/day. Doses above 40 mcg/kg/day have not been systematically evaluated in pediatric GHD populations.

If height velocity does not increase by at least 2 cm/year above baseline after 6 months of optimized dosing, the physician should reassess the diagnosis and consider switching to an FDA-approved somatropin product.

Monitoring Parameters and Safety Considerations

Laboratory Monitoring Schedule

Monitoring during off-label sermorelin therapy should follow a schedule adapted from the somatropin monitoring framework in the Endocrine Society's 2016 guideline [4], since no sermorelin-specific post-2008 guideline exists:

• IGF-1 and IGFBP-3: at 1 month, 3 months, then every 6 months
• Fasting glucose and HbA1c: at baseline and every 6 months (GH axis stimulation may impair insulin sensitivity)
• Thyroid function (free T4, TSH): at baseline and annually, since GH therapy can unmask central hypothyroidism [9]
• Bone age radiograph (left hand and wrist): every 6 months to assess skeletal maturation rate
• Height and weight: every 3 months, with height velocity calculated over each 6-month interval

Adverse Effects Known from Pre-Withdrawal Data

The adverse effect profile of sermorelin in pediatric patients, based on the Geref prescribing information and published trial data, includes injection-site reactions (erythema, pain, swelling) in approximately 17% of patients, headache in 5 to 10%, and flushing in 3 to 5% [8]. Antibody formation, as noted above, occurred in roughly 28% of patients. Gynecomastia was reported rarely in pubertal males.

Sermorelin does not directly suppress the hypothalamic-pituitary-adrenal axis, unlike supraphysiologic somatropin doses, but all GH-axis stimulation carries a theoretical risk of promoting insulin resistance and, in patients with undiagnosed intracranial tumors, accelerating tumor growth. A baseline brain MRI to rule out pituitary or hypothalamic lesions is standard practice before initiating any GH-axis therapy in a child [4].

When to Discontinue

Treatment should be stopped when bone age reaches 14 years in girls or 16 years in boys, or when epiphyseal fusion is confirmed radiographically, whichever comes first. Continued administration after epiphyseal closure provides no height benefit and may increase adverse-effect risk without therapeutic return.

Comparing Sermorelin with FDA-Approved Somatropin in Children

The most frequently cited reason practitioners give for considering sermorelin over somatropin is cost. Branded somatropin products carry annual list prices ranging from approximately $10,000 to $50,000 depending on dose and product. Compounded sermorelin at 30 mcg/kg/day for a 30 kg child costs roughly $150 to $300 per month at most 503B pharmacies, though this varies.

That cost difference is real, but several clinical factors favor somatropin:

Somatropin products are FDA-approved, manufactured under current Good Manufacturing Practice standards, and supported by post-market safety surveillance data covering millions of patient-years. The Pfizer International Growth Database (KIGS), which tracked over 83,000 children treated with somatropin across more than 50 countries, provides a rich safety and efficacy reference that no sermorelin dataset approaches in size or rigor [10].

The KIGS data showed that prepubertal children with isolated GHD treated with somatropin gained a mean of 10.7 cm in height standard deviation score over the first 2 years of treatment, with height velocity normalizing in the majority of patients within 12 months [10]. No comparable registry exists for sermorelin.

Somatropin is also effective in patients with partial or complete GH axis disruption, whereas sermorelin requires a functional pituitary capable of responding to GHRH stimulation. In children who have received cranial radiation or have structural pituitary lesions, sermorelin may produce inadequate GH release even at maximum doses.

Special Populations and Contraindications

Children with Hypothalamic GHD

In isolated hypothalamic GHD, where the pituitary itself is intact but GHRH secretion is deficient, sermorelin has theoretical appeal as a replacement for the missing signal. This is the population in which sermorelin's mechanism most closely addresses the underlying defect. Pre-withdrawal studies included children with hypothalamic GHD, and this subgroup appeared to respond well [5]. Pituitary GHD from structural damage remains a contraindication.

Children with Active Malignancy

Neither sermorelin nor somatropin should be initiated in children with active malignancy. GH axis stimulation has not been proven to cause de novo malignancy, but the theoretical concern about IGF-1-driven proliferation in existing tumor cells warrants caution. The Endocrine Society's guideline explicitly states that GH therapy is contraindicated in patients with active malignancy [4].

Neonates and Infants Under 2 Years

No clinical trial data support the use of sermorelin in infants under 2 years of age. The GHRH receptor system is functional in neonates, but dosing has not been characterized in this age group, and somatropin remains the standard for neonatal hypopituitarism presentations.

Practical Prescribing Guidance for Clinicians Considering Off-Label Use

Physicians who, after a thorough informed consent discussion, choose to prescribe compounded sermorelin for a pediatric patient with GHD should take the following steps to minimize risk and document clinical reasoning:

First, obtain two GH stimulation tests and document peak GH below 10 ng/mL. A single stimulation test is insufficient for diagnosis per Endocrine Society criteria [4].

Second, obtain baseline IGF-1, IGFBP-3, thyroid function, fasting glucose, bone age film, and brain MRI before starting any GH-axis therapy.

Third, use only a licensed 503B outsourcing facility that provides a Certificate of Analysis confirming potency, sterility, and endotoxin testing for each batch. The FDA maintains a list of registered 503B outsourcing facilities at fda.gov [7].

Fourth, document in the medical record that the off-label nature of this use, the absence of FDA approval, the availability of FDA-approved alternatives, and the compounded product's regulatory status were all explained to the patient's guardian, and that written informed consent was obtained.

Fifth, establish a clear 6-month reassessment point. If height velocity has not increased by at least 2 cm/year above the pre-treatment rate, the clinical rationale for continuing compounded sermorelin rather than switching to FDA-approved somatropin should be re-evaluated and documented.

The American Academy of Pediatrics Policy Statement on off-label drug use in children notes that off-label prescribing is common in pediatrics but requires "careful risk-benefit analysis, documentation, and appropriate monitoring" [11]. That framework applies directly here.

At the 6-month reassessment, if IGF-1 remains below the 50th age-adjusted percentile and height velocity gain is <2 cm/year, transition to an FDA-approved somatropin product at 25 to 35 mcg/kg/day should be the default recommendation.